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INTRODUCTION
Radiotherapy (RT) is an effective and commonly 
employed treatment in the management of more than half 
of human malignancies, and remains a standard therapeutic 
modality for breast cancer patients. However, tumors can 
be intrinsically resistant to RT or develop adaptive response 
and become resistant. Thus, the curative potential of RT 
is limited by the radioresistance of the tumor cells. The 
challenges in breast cancer management are to determine 
predictive factors that could help to define the subgroups 
of patients for whom aggressive local therapeutic option is 
not needed due to their intrinsic resistance, and determine 
the subgroups of patients who will really benefit from new 
treatment strategies after failure of RT.
Ionizing radiation (IR) kills cells via causing multiple 
forms of DNA damage. DNA double strand breaks (DSBs) 
represent the most dangerous type of DNA damage and is 
a determining factor of cellular radiosensitivity [1]. DSBs 
can also be caused by other sources, such as environmental 
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ABSTRACT
Radiotherapy (RT) remains a standard therapeutic modality for breast cancer 
patients. However, intrinsic or acquired resistance limits the efficacy of RT. Here, we 
demonstrate that CHK1 inhibitor AZD7762 alone significantly inhibited the growth 
of radioresistant breast cancer cells (RBCC). Given the critical role of ATR/CHK1 
signaling in suppressing oncogene-induced replication stress (RS), we hypothesize 
that CHK1 inhibition leads to the specific killing for RBCC due to its abrogation in the 
suppression of RS induced by oncogenes. In agreement, the expression of oncogenes 
c-Myc/CDC25A/c-Src/H-ras/E2F1 and DNA damage response (DDR) proteins ATR/
CHK1/BRCA1/CtIP were elevated in RBCC. AZD7762 exposure led to significantly 
higher levels of RS in RBCC, compared to the parental cells. The mechanisms by which 
CHK1 inhibition led to specific increase of RS in RBCC were related to the interruptions 
in the replication fork dynamics and the homologous recombination (HR). In summary, 
RBCC activate oncogenic pathways and thus depend upon mechanisms controlled by 
CHK1 signaling to maintain RS under control for survival. Our study provided the first 
example where upregulating RS by CHK1 inhibitor contributes to the specific killing 
of RBCC, and highlight the importance of the CHK1 as a potential target for treatment 
of radioresistant cancer cells.
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mutagens, chemotherapeutic drugs and any situations 
causing replication stress (RS) that is defined as slowing or 
stalling of replication fork progression and/or subsequent 
fork collapse. One major source causing RS is oncogene 
expression [2, 3]. DNA damage response (DDR) prevents the 
cells from lethality due to the damaged DNA via activation 
of cell cycle checkpoints, promotion of DNA repair, 
alteration of transcription and triggering apoptosis [4, 5]. 
Ataxia telangiectasia, and rad3-related (ATR) kinase and 
its downstream factor CHK1 are core elements of the DDR 
during replication stress. CHK1 is phosphorylated on serine 
317 and serine 345, respectively, by ATR, and these sites are 
required for the ability of CHK1 to amplify the signal by 
phosphorylating several additional targets [6, 7]. ATR/CHK1 
signaling is important for the cells survival in response to 
DNA damage agents that cause RS.
ATR/CHK1 is also essential for cell proliferation or 
viability in the absence of exogenous DNA damage [5, 8–11]. 
CHK1 promotes replication and transformation in an animal 
model by limiting oncogene-induced replication stress [12]. 
In this context, the generation of DNA damage, particularly 
DSBs induced by oncogenic stress, is suppressed by CHK1 
in order to provide the advantage of cell survival. Molecular 
mechanisms by which ATR/CHK1 maintain viability of 
cells and suppress oncogene-induced transformation in the 
absence of exogenous DNA damage are not fully understood. 
The role of ATR/CHK1 in inhibiting abnormal initiation and 
elongation of DNA replication [13– 15] and maintaining 
the stability of replication forks [16–18] and promoting 
replication fork restart could be important mechanisms [19]. 
Moreover. The role of ATR/CHK1 in homologous 
recombination (HR) could be also involved since HR is one of 
important mechanism that repair RS-induced DSBs [20–22]. 
Thus, ATR/CHK1 signaling is not only critical for the cell 
survival in the presence of exogenous DNA damage but also 
essential for cell survival in the absence of exogenous DNA 
damage, particularly during tumor development.
CHK1 inhibitors have been developed for clinical 
use, principally with the idea that they would be used to 
enhance killing of tumor cells by cytotoxic drugs or by 
radiation, via blocking cell cycle checkpoints, especially in 
p53 deficient cells [23–26]. Recent studies strongly suggest 
that sensitization activity of CHK1 inhibitor to IR and/or 
chemotherapeutic drugs is through a variety of mechanisms, 
such as inhibition of HR and/or interruption of replication 
fork stability [27–29]. In addition, although a previous 
report indicated that CHK1 inhibitor, as a single agent, has 
none or minimal role in antitumor activity [30], emerging 
data revealed that CHK1 inhibitor alone can specifically 
kill some tumor cells [31, 32]. However, the molecular 
mechanisms controlling the anti-tumor activity of CHK1 
inhibitor have not been identified.
The goal of our study is to define the differences of 
DDR between radiosensitive cells and radioresistant breast 
cancer cells (RBCC), and to seek for a better regimen 
targeting the radioresistance. Here, we report that oncogene 
proteins c-Myc/CDC25A/c-Src/H-ras/E2F1 and DDR 
proteins ATR/CHK1/BRCA1/CtIP are highly expressed 
in RBCC. CHK1 inhibition specifically targets RBCC via 
enhancing RS levels. Our studies, for the first time, apply 
the concept that increase RS by CHK1 inhibition can target 
RBCC. Our findings may be more broadly applicable for 
targeting cancers with similar characteristic as RBCC by 
CHK1 inhibitors. 
RESULTS 
CHK1 inhibitor, as a single agent, significantly 
suppresses the growth of cancer cells but fails to 
sensitize RBCC to IR
Given that CHK1 inhibitor has been reported to 
sensitize the advanced pancreatic cancer cells to IR [28], 
CHK1 inhibition could sensitize the RBCC to IR. In order 
to test this hypothesis, human breast cancer cells MCF-7 
and MDA-MB-231, and their corresponding IR -selected 
radioresistant cells (MCF-7/C6 and MDA-MB-231 FIR) 
were used [33, 34]. MCF-7 and MDA-MB-231 cells 
carry wild type p53 and mutant p53, respectively. We first 
detected the radio-sensitization activity of CHK1 inhibitor 
AZD7762 using colony formation assay. As we expected, 
MCF-7/C6 cells are more resistant to IR, compared to their 
own parental cells (Figure 1A). However, surprisingly, 
AZD7762 failed to sensitize MCF-7/C6 cells to IR 
(Figure 1B). Strikingly, we found that CHK1 inhibitor alone 
caused a dramatic suppression on cell growth in MCF-7/
C6 compared to MCF-7 cells (Figure 1C). This result was 
further confirmed by a second CHK1 inhibitor LY2603618 
(Figure S1A). Through measuring sub-G1 cells by flow 
cytometry, we determined the status of apoptosis. In both 
MCF-7 and MCF-7/C6, a pattern can be seen where there 
is a shift in the percentage of sub-G1 cells from viable to 
apoptosis as the dose escalates (Figure S2A, S2B). However, 
the percentage of sub-G1 phase cells is significantly higher 
in MCF-7/C6 cells, compared to control cells at the same 
conditions. This result was further confirmed by detecting 
the most optimal biomarkers of apoptosis, such as cleaved 
caspase 7, 9 and cleaved PARP proteins (Figure S2C). 
Thus, apoptosis is involved in cell killing induced by CHK1 
inhibition. However, we cannot exclude the possibility that 
other mechanisms of cell death are also involved, such as 
mitotic catastrophe. 
The result that CHK1 inhibitor alone caused a 
dramatic suppression on MCF-7/C6 cells was further 
supported by the second cell line MDA-MB-231 FIR 
(Figure 1D–1F) but the effect of CHK1 inhibition on cell 
growth is much less significant in MDA-MB-231 FIR 
(Figure 1F), compared to MCF-7/C6 cells (Figure 1C). 
Next, in order to further confirm the antitumor activity 
of CHK1 inhibitor in RBCC in vivo, we determined the 
efficacy of AZD7762 using tumor xenograft models. 
Groups of tumor-bearing mice were given CHK1 inhibitor 
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or DMSO i.p. daily for 3 days. Two cycles of CHK1 
inhibitor were given. For MCF-7/C6 xenografts, the data 
was analyzed as the time for the tumor volume to reach 
1500 mm3 (p < 0.0001) (Figure 1G, left panel). Clearly, 
there is a significant delay of tumor growth in the group 
with inhibitor treatment. Thus, the tumors growth is 
suppressed when CHK1 inhibitor is administrated in 
radioresistant MCF-7/C6 xenograft. In contrast, for MCF-7 
xenograft, the time for tumor volume to reach 1500 mm3 is 
similar in the group with or without treatment (Figure 1G, 
right panel). Taken together, our results described in Figure 
1 suggest that CHK1 inhibitor AZD7762, as a single agent, 
can significantly block the tumor growth of RBCC in both 
in vitro and in vivo assays. 
Increased expression of oncogene and DDR 
proteins are induced in RBCC 
We next ascertained the potential molecular 
mechanisms by which CHK1 inhibitor specifically targets 
RBCC. Given that oncogenes can be induced in response to 
IR [35] and ATR/CHK1 suppresses oncogenic stress [12], 
we hypothesized that CHK1 inhibition upregulates RS, 
therefore leading to specific cell killing of RBCC . In order 
to test this hypothesis, we first determined the expression of 
oncogene proteins that have been reported to cause RS [2, 3]. 
Notably, oncogenes c-Myc/CDC25A/c-Src/H-Ras/E2F1 
are induced in MCF-7/C6 and MDA-MB-231-FIR cells 
compared to MCF-7 and MDA-MB-231 cells, respectively, 
Figure 1: CHK1 inhibitor AZD7762 alone caused more cytotoxicity to RBCC but failed to sensitize RBCC to IR. 
(A) Clonogenic survival following IR. Survival experiments were repeated three times and the error bars in the graphs depicting the SD. 
Values marked with asterisks are significantly different (T-test, *p < 0.05, **p < 0.01). (B) CHK1 inhibitor (CHK1) failed to sensitize the 
MCF-7/C6 cells to IR. The cells were treated with AZD7762 (100 nM), then radiated 1 hr later. 24 hr after IR, the drug was removed from 
medium. (C) CHK1 inhibitor AZD7762 alone has more cytotoxicity to MCF-7/C6 cells compared to its own parental cells. Error bars 
represent the SD of three independent experiments (T-test, *p < 0.05, **p < 0.01). (D–F) CHK1 inhibitor AZD7762 alone induce more 
cytotoxicity in MDA-MB-231 FIR cells but AZD7762 failed to sensitize MDA-MB-231 FIR to IR. The methods and statistical analysis 
are the same as described in A–C. (G) Athymic nude mice bearing established MCF-7 or MCF-7/C6 tumors were treated with AZD7762 
(25 mg/kg) 2 cycles of therapy 3 days a week (arrows). AZD7762 treatment led to the tumor growth delay with MCF-7/C6 xenografts 
relative to tumors without treatment (T-test, p < 0.001). 
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although the magnitude of induction varies (Figure 2A). 
This result suggests that oncogenic pathways are induced 
in RBCC.
In support of this hypothesis, we found increased 
level of RS in RBCC via measurement of single strand 
DNA (ssDNA) using bromodeoxyuridine (BrdU) labelling 
(Figure 2B, Figure S3A). This assay is based on the 
observation that the nucleotide base analogue BrdU is 
recognized by an anti-BrdU antibody when incorporated 
into ssDNA but not DSBs [36, 37]. In response to RS, 
DSBs are often generated due to replication fork collapse. 
Correspondingly, we observed an increase in the proportion of 
cells positive for γ-H2AX foci, a marker of DSBs, in MCF-7/
C6 cells, compared to MCF-7 cells (Figure 2C, Figure S3B). 
To further verify that the increased γ-H2AX foci result from 
an accumulation of DSBs not ssDNA, we next performed 
comet assay under neutral conditions, which detects DSBs 
and not ssDNA [38]. Olive tail moment is increased in MCF-
7/C6 cells compared to MCF-7 cells (p < 0.05) (Figure 2D), 
indicating that RBCC exhibit accumulation of DNA DSBs. 
Yet, RBCC are able to proliferate in vitro and form tumors 
in vivo, suggesting that these cells have mechanisms in place 
to cope with RS. In support of the hypothesis that CHK1 
is part of the coping mechanism that inhibits oncogene-
induced replication stress, the expression of ATR/ CHK1 
were elevated in MCF-7/C6 and MDA-MB-231 FIR cells 
compared to parental cells (Figure 2E). In addition, the 
increased expression of HR proteins BRCA1 and CtIP were 
also observed in RBCC (Figure 2E). These results described 
in Figure 2 suggested that the oncogenes c-Myc/CDC25A/c-
Src/H-Ras/E2F1 that can cause replication stress and the 
DDR proteins ATR/ CHK1/BRCA1/CtIP that can promote 
HR are highly expressed in RBCC. In addition, basal level of 
RS increased in RBCC cells. 
Figure 2: Increased expression of oncogenes and elevated RS in RBCC. (A) The oncogenes c-Myc/Cdc25A/c-Src/H-ras/
E2F1 were induced in RBCC. (B) Higher levels of ssDNA accumulation in RBCC. The protocol for ssDNA detection has been 
described in previous publications [36, 37]. In brief, the cells were grown in the presence of bromodeoxyuridine (BrdU; 10 μg/ml; 
Invitrogen) for 24 h. After fixation, the cells were blocked and stained with anti-BrdU mouse monoclonal antibody clone B44 
(BD Biosciences, San Jose, CA) antibody. Then, the samples are incubated with an Alexa Fluor 488-conjugated goat anti-mouse antibody. 
Cells were scored positive when 10 nuclear foci were visible. The percentages of cells with BrdU foci are indicated. Error bars indicate SD 
from three independent experiments (T-test, **p < 0.01). (C) Higher levels of DSB in RBCC. The percentages of cells with γ-H2AX foci 
are indicated. In each experiment, 200 nuclei were counted per time. Error bars indicate SD from three independent experiments (T-test, 
**p < 0.01). (D) The neutral comet assay of genomic DNA of cells. The results are from three independent experiments (T-test, *p < 0.05). 
(E) Increased expression of ATR/CHK1/BRCA1/CtIP in RBCC.
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CHK1 inhibition upregulates RS, especially in 
RBCC
To determine the extent of RS following CHK1 
inhibition, we first analyzed foci of RPA2 and phosphorylated 
RPA2 (RPA2-P), the markers for RS in response to 
exogenous DNA damage agents by immunofluorescence 
staining. A more profound increase in the proportion of cells 
with RPA2 and RPA2-P foci was observed in MCF-7/C6 
cells compared to MCF-7 cells (Figure 3A, 3B). In support 
of the above hypothesis, the more significant increase of 
RPA2-P in RBCC cells treated with CHK1 inhibitor was also 
confirmed by WB (Figure 3C). In addition, CHK1 inhibition 
led to a more significant increase in γ-H2AX levels in 
MCF- 7/C6 cells, compared to MCF-7 cells (Figure 3D; 
Figure S4 left panel). A similar result was also observed in 
MDA-MB-231 FIR and parental cells (Figure 3E, 3F; Figure 
S4 right panel). Importantly, CHK1 activity was sufficiently 
suppressed in our experiments because treatment with CHK1 
inhibitor AZD7762 resulted in an increased CHK1 ser345 
phosphorylation and reduced global CHK1 protein levels 
(Figure 3D). It has been demonstrated that CHK1 ser345 
phosphorylation is a marker of CHK1 activation [39], 
which targets CHK1 protein to ubiquitination-dependent 
degradation [40]. In summary, we conclude that CHK1 
inhibition upregulates RS, especially in RBCC.
Since AZD7762 also inhibit CHK2 activity, we next 
determine how CHK1 or CHK2 knockdown affects RS in 
RBCC. CHK1 knockdown significantly led to increased 
γ-H2AX and RPA2- P foci whereas CHK2 knockdown has 
no detectable effect in RBCC (Figure S5A–S5C), arguing 
that CHK1 inhibition, instead of CHK2 inhibition by 
AZD7762, upregulated the extent of RS. These results were 
further confirmed by western blot (Figure S5D). Thus, the 
increased levels of RS, evidenced by the accumulation of 
DSBs and ssDNA are mainly due to the CHK1 inhibition 
rather than CHK2 inhibition.
CHK1 inhibition leads to the more significant 
increase in replication initiation in MCF-7/C6 
cells
Although the mechanisms by which oncogenes cause 
RS are not clear, increased origin firing and subsequent 
Figure 3: CHK1 inhibition led to the more significant increase in RS in RBCC. (A) Increased proportion of cells with foci 
of RPA2 or phosphorylated RPA2 (RPA2 S4/S8) in MCF-7/C6 cells. Data shown are averages from three independent experiments. Error 
bars represent the SD of three independent experiments (T-test, *p < 0.05 , **p < 0.01). (B) Representative foci of RPA2 (left panel) 
and RPA2 S4/S8 (right panel) are indicated. (C) Expression of RPA2 S4/S8. β-actin or RPA2 are used as loading controls (bottom row). 
(D) Accumulation of DSBs in MCF-7/C6 cells. The measurement of γ-H2AX by immunoblotting using an antibody raised against ser139 
phosphorylated of H2AX. The inhibition of CHK1 activity was monitored by the measurement of p-CHK1-345 and p-CHK1-317. (E–F) 
CHK1 inhibition led to the more significant increase in RPA2 S4/S8 and there is a space γ-H2AX in MDA-MB-231 FIR cells, compared 
to control cells. 
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nucleoid scarcity are critical reasons in current models [41]. 
If CHK1 inhibition abrogates the suppression of oncogenic 
stress, thus increased replication initiation should be 
observed, especially in radioresistant cells. In order to test 
our hypothesis, we first determined how CHK1 inhibitor 
affects DNA replication initiation by analyzing DNA fiber 
spreads. Cells were sequentially pulse-labeled with IdU and 
CldU for 40 min each, according to the protocol illustrated 
in Figure 4A . AZD7762 was added to the cell cultures 
during the CIdU pulse. IdU and CldU were detected with 
specific antibodies, in green and red, respectively. Origins 
of replication that were activated prior to the CldU pulse 
generated two bidirectional forks, each appearing as a green/
red or red/green signal (Figure 4B, signal a). Conversely, 
new origins that fired during the CldU pulse resulted in a 
green signal only (Figure 4B, signal b). We quantified the 
frequency of new origins in untreated and AZD7762-treated 
cells by dividing the number of green signals (b) by the 
sum of the green and green/red signals (a + b) (Figure 4B). 
The percentage of new origins increased when cells were 
treated with AZD7762 in both parental and MCF-7/C6 cells 
(Figure 4C), consistent with previous reports that ATR/
CHK1 inhibition or depletion increase origin firing in 
unperturbed cells [42, 43]. However, the magnitude of 
increase was more significant in MCF-7/C6, compared to 
parental cells, indicating that CHK1 inhibitor especially 
targets RBCC. 
CHK1 is involved in controlling replication initiation 
via regulating Cdc45 [44], a protein that is implicated in 
initiation rather than elongation processes. We next measured 
the amount of Cdc45 in non-extractable chromatin fraction. 
AZD7762 treatment caused a remarkable increase in the 
amount of non-extractable Cdc45 protein in MCF-7/C6 
cells, compared to MCF-7 cells (Figure 4D). This difference 
could not be accounted by the differences in Cdc45 levels, 
which were comparable in the two cell lines (Figure 4D). 
The effect of CHK1 inhibition on chromatin loading of 
Cdc45 was further confirmed by IF assay (Figure 4E, 4F). 
Moreover, Cdk inhibitor Ro3306 treatment abrogated the 
effect of CHK1 inhibitor on Cdc45 chromatin loading 
(Figure 4G), which is consistent with a previous report that 
CHK1 activity on replication initiation is mediated by Cdk 
activity [13]. Last, Cdk inhibition by Ro3306 prevented 
accumulation of γ-H2AX and RPA2-P in response 
to CHK1 inhibitor AZD7762 in RBCC (Figure 4G), 
suggesting that the increased initiation of DNA replication 
Figure 4: CHK1 inhibition led to the more profound increase in replication initiation in MCF-7/C6 cells. (A) Schematic 
of DNA fiber analysis. Green tracks, CldU; red tracks, IdU. (B) Schematic drawing and representative images of two replication signals 
from DNA fibers. At the top, two DNA replication forks moved bidirectionally from an origin (indicated by the diverging black arrows) that 
was activated before the CIdU pulse. Each fork was labeled with both IdU (red) and CldU (green). At the bottom, the replication bubble 
resulting from an origin that was activated during the CldU pulse produces a green-only signal. (C) Summary of new origins fired during 
labeling with CldU. The frequency (as a percentage) was calculated as the number of green signals (b in panel B) divided by the total 
(a + b) of green (b) plus green/red signals (a in panel B). Results are from three independent experiment results (T-test, *p < 0.05, 
**p < 0.01 ). (D) CHK1 inhibition led to increased levels of nonextractable Cdc45 protein in MCF-7/C6 cells. The cells treated with AZD7762 
(100 nM) for the indicated time were incubated with extraction buffer for 5 min on ice, and processed for Western blotting (top panel). 
The whole lysate protein is used as a control (bottom panel). (E) Measurement of Cdc45 chromatin loading after preextraction of cells 
with detergent by immunostaining. Cells presenting with Cdc45 staining were considered positive. The results are from three independent 
experiments. Error bars represent the SD of three independent experiments (T-test, **p < 0.01). (F) Representative Cdc45 staining (green) 
in MCF-7 and MCF-7/C6 cells are presented. Cell nuclei were stained with DAPI (blue). (G)The effect of CHK1 inhibition on RS in RBCC 
depends on Cdk activity. Cdk activity was inhibited by inhibitor Ro3306. 
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likely contributes to DSBs generation seen after CHK1 
inhibition in radioresistant breast cancer cells. Cumulatively, 
the results presented in Figure 5 suggest that CHK1 
inhibition leads to a significant increase in Cdc45-mediated 
replication initiation in RBCC.
CHK1 inhibition leads to a significant decrease 
in replication fork speed and deoxynucleotide 
supply in RBCC
Using DNA fiber assay, we next determined how 
CHK1 inhibition affects replication fork speed in parental 
and radioresistant cells. We predicted that CHK1 inhibition 
would reduce replication fork speed due to the increasing 
origin firing [45]. The significant decrease in the speed of 
replication fork progress was observed in both MCF-7 and 
MCF-7/C6 cells when CHK1 activity is inhibited (Figure 
5A, 5B). However, the magnitude of the decrease is more 
significant in MCF-7/C6 cells compared to MCF-7 cells 
(Figure 5A). These results show that CHK1 inhibition 
slows down fork progression while increasing origin firing 
(replication initiation) in breast cancer cells, and that the 
effect is more robust in RBCC (Figure 5A, 5B). These data 
are also consistent with the report that CHK1 promotes 
replication fork progression by controlling replication origin 
activity [14]. Although it is not known how the increased 
origin firing could lead to slow replication fork progression, 
the imbalance in dNTP pools can cause dysfunctional 
replication [46, 47]. Thus, we next determined dATP levels 
by Liquid chromatography-tandem mass spectrometry 
(LC-MS/MS). Indeed, dATP levels was reduced by 60% 
following CHK1 inhibitor treatment in MCF-7/C6 cells 
which is significantly higher than the 36% reduction 
seen in MCF-7 cells (Figure 5C), indicating that CHK1 
inhibition led to the increased deoxynucleotide consumption, 
especially in RBCC. Interestingly, a similar phenotype 
was found in MDA-MB-231 pairs (Figure 5D–5F), but 
with some differences. CHK1 inhibition has an equivalent 
effect on replication initiation (Figure 5D) and fork speed 
(Figure 5E) in parental MDA-MB-231 and radioresistant 
MDA-MB-231 FIR cells. However, CHK1 inhibition failed 
to cause scarcity of dNTP pool in both MDA-MB-231 and 
MDA-MB-231 FIR cells (Figure 5F). These results suggest 
that the increased replication firing may not necessarily lead 
to depletion of dNTP pool in all types of tumor cells, and 
also that the mechanisms by which CHK1 inhibition leads 
to increased levels of RS may be not be limited to regulation 
in replication initiation and nucleotide pool balance. 
Figure 5: CHK1 inhibition led to the more significant decrease in replication speed and deoxynucleotide supply in 
MCF-7/C6 cells. (A) A more significant decrease of replication fork speeds in MCF-7/C6, compared to parental MCF-7 cells following 
100 nM AZD7762 treatment. Schematic of DNA fiber analysis is the same as described in Figure 5A. The IdU/CIdU ratio was used to 
determine elongation. Means and standard deviation (S.D.) of three independent experiments are shown. Values marked with asterisks are 
significantly different (T-test, *p < 0.05, **p < 0.01). (B) Representative images of replication tracks from cells treated with or without 
AZD7762 (100 nm). (C) Quantitative determination of ATP and dATP in cell lysates was conducted by LC-MS/MS method. Y axis 
represents the ratio of dATP/ATP. The details see material and method (T-test, **p < 0.01 , ***p < 0.001). (D–F) CHK1 inhibition had a 
similar effect on replication dynamics and deoxynucleotide supply in MDA-MB-231 and MDA-MB-231 FIR cells. (D) Summary of new 
origins fired during labeling with CldU. (E) Replication track length analyzed by DNA fiber spreading. Means and standard deviation (S.D.) 
The graph is the average of three independent experiments (T-test, **p < 0.01). (F) Quantitative determination of ATP and dATP in MDA-
MB-231 and MDA-MB-231 FIR cells (NS, no significant difference). 
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CHK1 inhibition leads to more significant 
decrease in HR activity in RBCC
In addition to interruption of replication dynamics, 
CHK1 inhibition may also impair HR. HR is a mechanism 
that suppresses RS induced by oncogenes, by promoting 
the repair of DSBs that result from replication fork 
collapse. Thus, we next determine the role of CHK1 
inhibitor in HR activity in both parental and RBCC by HR 
reporter DR-GFP as described previously [36, 48–51]. In 
this system, a DSB is generated by expressing the I-SceI 
endonuclease. Repair of the cleaved I-SceI site by gene 
conversion-associated HR gives rise to a functional GFP 
gene when the template used for repair is a truncated GFP 
fragment located downstream in the plasmid. HR activity 
is measured by flow cytometric analysis of the number of 
GFP+ cells following I-SceI expression [51]. The parental 
MCF-7 cells and MCF-7/C6 cells with chromosome 
integration of DR-GFP were established using a standard 
method [50]. Using the established system, an increased 
frequency of HR in MCF-7/C6 and MDA-MB-231 FIR 
cells was observed, compared to their own parental cells 
(Figure 6A). The increased HR in RBCC co-related with 
the increased expression of ATR/CHK1/BRCA1/CtIP since 
these proteins are important for HR activity [20, 21, 52, 53]. 
The increased HR activity was not caused by the alteration 
of the cell cycle because identical cell cycle profiles were 
observed in radioresistant cells and their corresponding 
parental cells (Figure 6B). We found that CHK1 inhibition 
leads to a more significant decrease in HR in RBCC, 
compared to parental cells. Collectively, these data suggest 
that CHK1 inhibition results in a significant decrease in HR 
activity, particular in RBCC cells. This result is consistent 
with the observation that CHK1 inhibition led to a more 
profound increase in RS in RBCC (Figure 3). Thus, RBCC 
cells most likely depend on HR activity for survival 
because HR is a major mechanism counteracting the DNA 
damage caused by RS.
DISCUSSION 
Chemotherapeutic drugs that as single agents can 
specifically target radioresistant cancer cells are rarely 
reported and studied although continuing efforts have 
been conducted to identify radiosensitizing agents that 
preferentially sensitize tumor cells to the cytotoxic action 
Figure 6: CHK1 inhibition resulted in a more significant decrease in HR in RBCC. (A) AZD7762 exposure led to decreased 
HR-mediated repair, particularly in RBCC. HR was detected using chromosomally integrated HR substrate (DR-GFP) which is based on 
reconstitution of the EGFP (from M. Jasin). HR induced by I-SceI was measured by dual-color flow cytometric detection of GFP-positive 
cells. In brief, the cells were transfected with I-SceI and then AZD7762 (100 nM) was added to the medium 24 hr after transfection. HR was 
measured 24 hr after the addition of AZD7762. Error bars represent the SD of three independent experiments (T-test, *p < 0.05 , **p < 0.01 , 
***p < 0.001). (B) Cell cycle profiles are indicated. Cell cycle was analyzed by flow cytometry. Results are means from three independent 
experiments. Error bars represent the SD of three independent experiments (NS, no significant difference).
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of RT. In contrast to the common paradigm that CHK1 
inhibitor can be used as a radiosensitizer, in this study 
we report that CHK1 inhibitor, as a single agent, can 
specifically target RBCC via regulation of RS (Figure 7), 
reducing the growth of tumor cells in vitro and in vivo. Thus, 
CHK1 inhibition may provide therapeutic opportunities in 
the radioresistant breast cancer patients. 
Oncogene proteins and DDR proteins are 
induced in RBCC
Oncogenes c-Myc/CDC25A/c-Src/H-Ras/E2F1 and 
DDR proteins ATR/CHK1/BRCA1/CtIP are also highly 
expressed in RBCC (Figure 2). The physiological 
significance of the increase in the expression of both 
oncogene proteins and DDR proteins in RBCC is not fully 
understood. However, according to the oncogene-induced 
DNA damage model of cancer progression [2, 3], oncogenes 
generate substantial amounts of RS, which in turn activate 
the DDR. Activation of DDR is important to limit the 
expansion of tumor cells with RS [54–56], since RS causes 
the genomic instability that facilitates the acquisition of 
secondary hits in the genome that promote malignancy. To 
minimize the impact of this effect and to maintain the fitness 
of the cell, the activation of oncogenes is often associated 
with compensatory molecular changes, processes mediated 
in part by the ATM and ATR protein kinases [19]. If this is 
the case, the induced oncogene expression developed during 
RT could be toxic to cells due to RS increase. However, 
the increased ATR/CHK1/BRCA1/CtIP expression may 
constitute a key step to enhance cellular tolerance to 
oncogenic stress, considering their roles in suppression of 
abnormal replication initiation and promotion of HR, which 
are two important mechanisms suppressing oncogenic stress 
[12, 22]. Therefore, radioresistant cells are selected because 
they confer a growth advantage by overcoming the toxicity 
of oncogenic stress via enhancing DDR protein expression 
during RT therapy. 
Currently, considerations for radiotherapy are 
determined by the clinical factors rather than molecular 
subtypes and pathways, which might result in the 
unnecessary treatment for the patients who are intrinsically 
resistant to IR. Whether higher expression of oncogene 
proteins c-Myc/CDC25A/c-Src/H-ras/E2F1 and DDR 
proteins ATR/CHK1/BRCA1/CTIP can be used as indicators 
for the predication of radioresistance need to be determined 
in the clinic in the future. 
Induced essentiality and targeting RBCC by 
CHK1 inhibitor 
Several concepts originated in genetics have been 
applied to cancer therapy. “Synthetic lethality” describes the 
situation where a defect in one gene or protein is compatible 
Figure 7: A proposed model for targeting RBCC cells by CHK1 inhibitor via abrogating the suppression in RS induced 
by oncogenes. (A) The RBCC express high levels of DDR proteins and oncogene proteins, including ATR/CHK1/BRCA1/CtIP and 
c-Myc/CDC25A/c-Src/H-ras/E2F1. The increased expression of DDR protein would be an important mechanism suppressing oncogenic 
stress by inhibiting aberrant replication initiation and promoting HR. Therefore, the damages caused by oncogenic stress in RBCC are 
minimal and the RBCC with high levels of expression of oncogene proteins survive. (B) CHK1 inhibition enhances oncogenic stress by 
abrogating the suppression of replication initiation and/or interrupting HR activity, which leads to the accumulation of massive ssDNA/
DSBs and subsequent death of RBCC. 
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with cell viability but results in cell death when combined 
(synthesized) with another gene or protein defect. This 
concept has been practically applied for the treatment of 
breast cancer patients that are defective in BRCA1/2 with 
PARP inhibitors [57, 58]. “Induced essentiality” is an 
extension of synthetic lethality [59] that refers to a new 
state in which mutation of a gene drives the tumorigenic 
phenotype of the cells but also has potentially deleterious 
effects on cell fitness. Activity of a second gene mitigates 
the deleterious effects of the mutation of the first gene. 
Thus, the second gene/protein is essential for cell survival. 
We speculate that the increased DDR protein expression is 
important for the survival of radioresistant cells where the 
oncogenes are highly expressed. It is noteworthy that in 
our study we observed a more effective antitumor activity 
by CHK1 inhibition in RBCC where the oncogenes are 
highly expressed (Figures 1, 2). Therefore, it is possible that 
targeting radioresistant cancer cells with CHK1 inhibitor 
is an extension of the concept of “Induced Essentiality” 
to cancer therapy. In support of this concept, ATR/
CHK1 pathway inhibition in combination with oncogene 
expression of H-rasG12V cells elevate H2AX phosphorylation 
to significantly higher levels than produced in control cells 
[55], and also ATR/CHK1 inhibitors are highly effective in 
killing Myc-driven lymphomas [56]. Thus, the greatest effect 
of CHK1 inhibition in cancer treatment may be achieved in 
different types of cancer cells with similar characteristic as 
RBCC, based on the same logic. This hypothesis needs to be 
intensively tested in future. 
Several potential mechanisms could contribute to this 
specific targeting of RBCC by CHK1 inhibitor. First, the 
radioresistant cells may rely on ATR/CHK1/BRCA1/CTIP 
for survival in the absence of exogenous DNA damage due 
to their critical role in inhibition of replication initiation and/
or HR promotion as we discussed above. Second, one of 
the major differences between radioresistant and parental 
cells is that RBCC carry a high level of RS (Figure 2). 
The additional DNA damage, as a result of the increased 
replication initiation by CHK1 inhibition, may saturate the 
DSBs repair ability. Under conditions of proficient DNA 
repair, both radioresistant and parental cells may be able 
to accomplish full repair. However, if HR is inhibited, the 
radio-resistant cell’s additional burden of lesions saturates 
the DNA repair capacity and specifically sensitizes the 
tumor cells relative to the normal. The increased burden of 
DNA DSBs and the impaired HR due to CHK1 inhibition 
provide a synthetic lethal interaction that would be selective 
for RBCC. These differences between parental and RBCC 
provide a unique opportunity to target RBCC.
The radiosensitization activity of CHK1 inhibitor 
was observed in previous studies [23, 24, 28], perhaps due 
to the interruption of G2/M arrest and HR activity [28]. 
In our study, CHK1 inhibitor failed to sensitize RBCC to 
IR although HR activity and G2/M arrest in RBCC are 
abrogated by CHK1 inhibitor (Figure 6, data not shown). 
These results suggest that the defects on HR and G2/M 
arrest may not necessarily sensitize RBCC to IR. This result 
is consistent with the fact that G2/M phase checkpoint plays 
a minimal role in radio sensitivity [60]. In addition, HR is 
less important than Non-homologous end joining (NHEJ) 
for repair of IR-induced DSBs, although this pathway is 
critical for the repair of DSBs that originate during DNA 
replication in S phase cells. Thus, it is most likely that 
regardless of the impairment of HR and G2/M arrest caused 
by CHK1 inhibition, NHEJ pathway can be still active or 
upregulated in RBCC cells, which could sufficiently repair 
DSBs induced by IR. In support of this hypothesis, NHEJ 
activity is significantly higher in RBCC, compared to 
parental cells (data not shown). Thus, multiple mechanisms 
contribute to the radioresistance of RBCC. Blockage of HR 
and G2/M arrest by CHK1 inhibitor are not sufficient to 
sensitize these cells to IR.
CHK1 inhibition increases RS levels in RBCC
Our results suggest that CHK1 inhibitor targets RBCC 
via regulation of RS caused by oncogenes (Figure 3). The 
mechanisms by which oncogenes induce RS have not been 
clearly defined. According to a current model, oncogene-
induced RS is a result of hyper-replication, with an increase 
in replication initiation and the subsequent scarcity of 
replication factors, such as nucleotides [61]. The cellular 
availability of nucleotides may not be sufficient to carry 
out replication under conditions where a massive number 
of origins are fired simultaneously, thus slowing replication 
fork. Subsequently, ssDNA and DSBs are induced, and 
cell death occurs as a result of massive DNA damage. In 
support of our hypothesis that CHK1 inhibitor kills RBCC 
via upregulation of oncogenic stress, we find a significant 
increase in the firing of replication initiation, a decrease in 
dNTP pool, and a reduction in fork progression in MCF-7/C6 
cells, in comparison to parental control cells (Figures 4, 5). 
However, this may not explain all since CHK1 inhibition 
enhances cell killing and replication stress in MDA-MB-231 
FIR cells compared to MDA-MB-231 cells. However, the 
effect of CHK1 inhibitor on replication initiation/fork 
speed and dATP pool is similar in MDA-MB-231 FIR and 
MDA-MB-231 cells. Since HR activity is also an important 
mechanism suppressing oncogenic stress the effect of CHK1 
inhibition in HR activity may contribute to the specific 
killing of MDA-MB-231 FIR cells (Figure 6). In our study, 
only limited oncogene expression was detected (Figure 2A). 
Given that different oncogenes cause RS via distinct 
mechanisms, it could be possible that the effect of CHK1 
inhibition on replication initiation might depend upon the 
context of tumor cells. 
In conclusion, we propose a model in which CHK1 
inhibitor can be used to specifically target RBCC. CHK1 
specifically limits RS by inhibiting replication initiation 
and promoting HR in RBCC. In normal conditions, 
RBCC survive even with high levels of induced oncogene 
expression during RT (Figure 7A). However, when CHK1 
activity is inhibited, the suppression of replication initiation is 
abrogated, which leads to increased amounts of DSBs. On the 
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other hand, the decreased HR activity due to CHK1 inhibition 
could also result in a failure to repair DSBs (Figure 7B). The 
dual roles of CHK1 inhibitor in interruption of replication 
initiation and HR contribute to its antitumor activity in RBCC 
(Figure 7). In our model, targeting RBCC and upregulating 
RS by CHK1 inhibition appears to be independent of p53 
since CHK1 inhibition leads to more cell killing and the more 
profound increase in RS, compared to their parental cells 
regardless of the status of p53 (Figures 1, 3). Our result is 
consistent with a recent publication indicating that oncogenic 
stress sensitizes murine cancers to hypomorphic suppression 
of ATR, and the toxic interaction between ATR suppression 
and oncogenic stress occurred independent of p53 status 
[54]. However, we cannot exclude the possibility that p53 is 
involved to certain extent, because a remarkable cell killing by 
CHK1 inhibitor is observed in wild type p53 expressing cells 
(MCF-7/C6) in comparison to mutant p53 expressing cells 
(MDA-MB-231 FIR) (Figure 1).
In summary, our study reveals that upregulation of 
RS could be a promising strategy targeting radioresistant 
breast cancer cells by CHK1 inhibition. In addition, it is 
conceivable that RBCC or any situations harboring same 
characteristics as RBCC may be prime candidates for 
treatments utilizing CHK1 inhibition. 
MATERIALS AND METHODS
Cell lines, infections, transfections and inhibitors 
Parental cells and their corresponding radioresistant 
derivatives were obtained from JianJian Li (University of 
California Davis). MCF-7 and MCF-7/C6 cells were cultured 
in Minimum Essential Medium (MEM, lifetechnologies) 
supplemented with 10% bovine growth serum, 100 U/ml 
penicillin and 100 μg/ml streptomycin at 37°C, 5% CO2. 
MDA-MB-231 and MDA-MB-231 FIR cells were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM with Low 
Glucose, HyClone) supplemented with 10% bovine growth 
serum, 100 U/ml penicillin and 100 μg/ml streptomycin 
at 37°C, 5% CO2. MCF-7/C6 cells with chromosomal 
integration of the DR-GFP reporter were generated according 
to a standard protocol. CHK1 and CHK2 short-hairpin 
RNAs (shRNA) were purchased from Sigma. All DNA 
plasmid transfections were performed using Lipofectamine 
2000 according to the manufacturer’s recommendations 
(Invitrogen, Carlsbad, CA). The CHK1 inhibitors AZD7762 
and LY2603618 were purchased from Selleckchem and 
ApexBio, respectively. The Cdk inhibitor Ro3306 was 
purchased from Tocris. 
Immunoblotting
The following conditions are used. Anti-BRCA1 
(Clone D-9, 1:200, Santa Cruz Technology); Anti-RAD51 
(Clone H92; 1:200; Santa Cruz Technology); Anti-BRCA2 
(Clone 5.23, 1:500, EMD Millipore); Anti-RAD52 (Clone 
5H9, 1:200, GeneTex); anti-RPA2 (Clone NA18, 1:100, 
Calbiochem/EMD Millipore); Anti-53BP1(Clone 1B9, 
1:1000, Novus biologicals); Anti-E2F1(Clone KH95, 
1:200, Santa Cruz Technology); Anti-β-Actin ( Clone AC-
74, 1:10000, Sigma-Aldrich); Anti Mre11 (1:1000, Novus 
Biologicals); Anti-CHK1 (G-4, 1:500, Cell signaling); 
Phospho-CHK1 antibody (#2344 CHK1-pSer317,1:500; 
Cell signaling);  Phospho- CHK1 antibody (#133D3 
CHK1-pSer345, 1:500, Cell signaling); Anti c-Myc 
(9E10 sc40, 1:300,Cell signal), Anti E2F1 (clone KH95 
sc-251, 1:500,Cell signaling); H-ras(F235 sc-29, 1:50, 
cell signaling); c-Src(N-16 sc-19, 1:50, cell signaling); 
Anti Cdc45 (G-12 sc55569, 1:50, Santa Cruz); γ-H2Ax 
(ser139 JBC301, 1:500, Millipore clone); rabbit polyclonal 
antibody phosphor RPA32 Ser4/Ser8 (Bethyl, BL647, 
1: 1000 dilution), Anti CDC25A (clone DCS-120, 1:100, 
Thermo scientific); Cdk2 (610146, 1:200,BD Biosciences); 
cyclin E (sc247, 1:200, Santa Cruz Technology) for western 
blotting.Secondary antibodies used were goat-anti-mouse 
IgG–horseradish peroxidase (HRP) conjugated, goat-anti-
rabbit IgG–HRP conjugated at 1:1000 dilutions. Radiation 
was delivered to cultured cells using a cesium-137 gamma 
ray at a dose rate of 3.1 Gray /min.
Immunofluorescence analysis 
Mouse anti-γ-H2AX (Ser139, clone JBW301, 
millipore) was used at 1:500 dilution. The monoclonal 
anti-BrdU antibody (BD Biosciences) was used at 1:200 
concentration. Rabbit anti- RPA32 (S4/S8) [A300-245A, 
BETHYL] were used at 1:500 dilution. For analysis of 
Cdc45 chromatin staining, a detergent extraction method was 
employed as described previously (9). Rabbit anti-Cdc45 
(H- 300, clone, sc20685, Santa Cruz) was used 1:50 dilution. 
The secondary antibody, goat–anti-mouse IgG Alexa fluor 
594 or FITC-conjugated anti-mouse secondary antibody 
(sigma) was used at 1:400 dilution. The slides were viewed 
at 1000 × magnification on an NIKON 90i fluorescence 
microscope (photometric cooled mono CCD camera). 
Homologous recombination assay 
HR was measured in cells according to previous 
publications [50].
Cell cycle analysis 
Cell Cycle Analysis was conducted as we described 
previously [50]. 
Comet assay
Cells were analyzed by the Comet assay under 
neutral conditions (Trevigen, Gaithersburg, MD). Comets 
were analyzed using CometScore software (TriTek, 
Sumerduck, VA). 
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Colony formation assay
Clonogenic analysis was performed as described 
in reference [50]. Colonies containing > 50 cells were 
counted. 
DNA fiber assay
DNA fiber assay were performed as published 
previously [62]. The replication fibers were viewed 
at 1000× magnification on an NIKON 90i fluorescence 
microscope (photometric cooled mono CCD camera). 
Signals were measured by using Image J software (NCI/
NIH), with some modifications made specifically to measure 
DNA fibers.
LC-MS/MS method for quantitative 
determination of ATP and dATP in cell lysate
The cells (1 × 107) were suspended in 0.5 ml of 80% 
methanol aqueous solution. The mixture went through a 
process of freezing (−80°C) and thawing (room temperature) 
for 3 times, followed by a sonication for 10 min, and then 
centrifuged. The supernatant was dried with N2. The residue 
was dissolved in 400 μl of 10 mM ammonium formate 
solution, and 100 μl of the solution was used for LC-MS 
analysis. The separation of analytes was carried out on an 
XTerra C18 column (2.1 × 100 mm) using a gradient elution 
from 20% B to 80% B in 12 min at a flow rate of 0.2 ml/min. 
The mobile phase A was 1 mM tributylamine and 0.25 
mM acetic acid aqueous solution, and mobile phase B was 
90% methanol with 1 mM tributylamine and 0.25 mM 
acetic acid. All calibrators, internal standards (ATP-d4 
and dATP-13C10,15N5), and QC samples were prepared 
in 10 mM ammonium formate solution. 10 μl of samples 
was injected. This method has a linear calibration range of 
5.00–500 ng/ ml for dATP and 100–50000 ng/ml for ATP. 
The API 3200 mass spectrometer was operated using ESI– . 
Quantitation was done by MRM mode with the following 
parameters: m/z 506 > 273 for ATP, m/z 510 > 159 for 
ATP-d4, m/z 490 > 159 for dATP, m/z 505 > 159 for dATP-
13C10,15N5, dwell time at 50 ms, declustering potential 
(DP) at −53 V, entrance potential (EP) at −6.0 V, collision 
energy (CE) at −30 V, collision cell exit potential (CXP) 
at −6.0 V, curtain gas (CUR) at 25, collision gas (CAD) at 
3, ionspray voltage (IS) at −4500V, temperature (TEM) at 
600°C, ion source gas 1 (GS1) at 50, ion source gas 2 (GS2) 
at 50, and resolutions were set at unit for both Q1 and Q3.
Xenograft studies
Female athymic nude mice, 4–5 weeks of age, bred 
in Case Western Reserve University, were used for this 
study. All experiments were carried out under a protocol 
approved by the National Cancer Institute Animal Care and 
Use Committee and were in compliance with the Guide 
for the Care and Use Of Laboratory Animal Resource, 
(1996) National Research Council. For tumor growth delay 
studies, Implant the 17β-ESTRADIOL(innovative research 
of America cat#NE-121 0.72 mg/pellet 90-day release) into 
the mice on the neck one week prior to cells injection, then 
8 × 106  cells were suspended and then injected subcutaneously 
into flanks. Tumor growth was followed until the diameter 
of tumor reached 0.6–0.8 cm. At this point animals were 
randomized into 2 groups (8 mice/group): control and 
AZD7762. AZD7762 (25 mg/kg) was administered by i.p. 
injection at 2,3,5 days (once a day) as a cycle for 2 cycles. 
Students T-test was used to calculate the delay of two group 
and p-values for the differences between the various groups.
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